Polomar Health Services, Inc.

Polomar Health Services, Inc. announced significant changes to its Board of Directors and management team. David Spiegel and Terrence M. Tierney resigned as directors, though Mr. Tierney remains Interim CEO. The Board's size was fixed at five, with George Hornig, Alexandra Peterson, Gabrielle Toledano, and George Caruolo elected as new directors, joining incumbent Gabriel Del Virginia. Additionally, George Hornig was appointed Executive Chairman and Chair of the Board, Terrence M. Tierney as Interim CEO, and Timothy M. Papp as Secretary and General Counsel. A Special Committee was also established to review a proposed acquisition of intellectual property from affiliated Series A Convertible Preferred Stock holders.

Polomar Health Services, Inc. announced the appointment of Douglas Beck as its new Chief Financial Officer and Treasurer, effective July 15, 2026. In this role, Mr. Beck will also serve as the company's principal financial and accounting officer. He brings extensive experience, having previously held CFO positions at AiAdvertising, Inc., ShiftPixy, Inc., and Beyond Air Inc.

Polomar Health Services, Inc. announced a change in its independent registered public accounting firm. On July 8, 2026, the company dismissed GreenGrowth CPAs and appointed Haskell & White LLP. The company stated that GreenGrowth's reports for 2024 and 2025 did not contain adverse opinions or disclaimers, and there were no disagreements or reportable events with the former auditor. Haskell & White will perform the audit for the fiscal year ending December 31, 2026, and review interim financial information.

Polomar Health Services, Inc. announced significant changes to its Board of Directors and executive leadership. David Spiegel and Terrence M. Tierney resigned as directors, leading to the election of four new directors: George Hornig, Alexandra Peterson, Gabrielle Toledano, and George Caruolo. The Board also appointed George Hornig as Executive Chairman, Terrence M. Tierney as Interim CEO, and Timothy M. Papp as Secretary and General Counsel. Additionally, the Board reconstituted its committees and established a Special Committee to review a proposed acquisition of intellectual property.

Polomar Health Services, Inc. announced the mutual termination of its Agreement and Plan of Merger with Altanine, Inc., originally dated July 23, 2025. The companies determined the merger was no longer in their best interests. Concurrently, Polomar and Pinata Holdings, Inc. (a subsidiary of Altanine) terminated their Know How and Patent License Agreement. Polomar has a grace period until September 7, 2026, to dispose of any remaining inventory related to the patent agreement. As part of the termination, Polomar will pay Altanine $36,000.

Polomar Health Services, Inc. (PMHS) filed its Form 10-Q for the period ending March 31, 2026. The company reported a significant increase in revenue to $1,005,519 from $4,542 in the prior year, leading to a narrowed net loss of $25,377 compared to $456,855 in the same period last year. Despite the improved operational performance, the company's total liabilities exceeded its total assets, resulting in a substantial stockholders' deficit. The filing also details various corporate actions, loan agreements, and business developments, including the planned launch of the SlimRx online platform and ongoing discussions with marketing partners.

Polomar Health Services, Inc. and Altanine, Inc. executed a Consent and Waiver Letter on May 11, 2026, waiving several key conditions for their merger, including the S-4 registration statement effectiveness, Nasdaq listing approval, a $25 million equity credit line, a reverse stock split to achieve a $10 share price, and the completion of concurrent financing. This waiver aims to expedite the merger's closing. Additionally, Polomar amended its CEO Terrence M. Tierney's employment agreement, outlining his transition to Executive Vice President and COO post-merger, adjusting his base salary, and detailing new stock option grants and vesting schedules.

Polomar Health Services, Inc. (PMHS) detailed its ongoing strategic initiatives, including the completed merger with Polomar Specialty Pharmacy, LLC, a name change, and a 1-for-10 reverse stock split. The company also announced the intent of ForHumanity Health, Inc. to terminate their Product Fulfillment and Distribution Agreement for VigorAir™, a significant setback. Additionally, PMHS is pursuing a merger with Altanine Inc., which is still pending and, if completed, would result in Altanine stockholders owning approximately 80% of the combined entity and a new management structure. The company acknowledges its status as a development-stage entity with a history of losses, an unproven business plan, and identified material weaknesses in internal controls.

Polomar Health Services, Inc. announced the termination notice of its Product Fulfillment and Distribution Agreement with ForHumanity, Inc. The agreement, which granted ForHumanity exclusive marketing rights for certain PMHS pharmaceutical products, included a guaranteed payment of $750,000 to Polomar, with $500,000 already received. ForHumanity claims false representations by Polomar, while Polomar denies these claims, asserting ForHumanity is in default and lacks standing to terminate the agreement.